How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Gene Vector Market
- By Vector Type: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral (AAV) Vectors, Retroviral Vectors, Herpes Simplex Virus (HSV) Vectors
- By Application: Gene Therapy, Vaccine Development, Cancer Immunotherapy, Regenerative Medicine, Research and Development
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Hospitals and Clinics
- By Production Method: Transient Transfection, Stable Producer Cell Lines, Helper Virus-Based Production, Baculovirus Expression System
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Adenoviral Vectors leads By Vector Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Gene Vector Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Vector Type 5
Application 5
End User 4
Production Method 4
Companies profiled
Thermo Fisher Scientific
Lonza Group
Sartorius AG
Miltenyi Biotec
Cytiva (part of Danaher Corporation)
Viralgen
REGENXBIO
Oxford Biomedica
SIRION Biotech
Bayer AG (through its gene therapy and vector manufacturing divisions)
Catalent Inc.
Brammer Bio (a Catalent company)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Lonza Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Miltenyi Biotec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cytiva (part of Danaher Corporation)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Viralgen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →REGENXBIO
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Oxford Biomedica
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →SIRION Biotech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bayer AG (through its gene therapy and vector manufacturing divisions)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Catalent Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Brammer Bio (a Catalent company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Paragon Bioservices (a Catalent company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →AGC Biologics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →WuXi AppTec
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,130M by 2033 · 3.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Adenoviral Vectors32.4
- Lentiviral Vectors16.3
- Adeno-Associated Viral (AAV) Vectors19.5
- Retroviral Vectors17.3
- Herpes Simplex Virus (HSV) Vectors14.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$536.6M → $656.5M · 2.6%
Europe$374.0M → $536.5M · 4.6%
Asia Pacific$341.5M → $434.2M · 3.0%
Latin America$211.4M → $276.0M · 3.4%
Middle East and Africa$162.6M → $197.9M · 2.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.382026
3.412027
3.412028
3.422029
3.432030
3.452031
3.452032
3.472033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific15.3
- Lonza Group25.9
- Sartorius AG7.8
- Miltenyi Biotec5.9
- Cytiva (part of Danaher Corporation)6.0
- Viralgen11.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Vector Type27.3%
Application18.2%
End User18.1%
Production Method36.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.2
- Europe25.5
- Asia Pacific20.7
- Latin America13.1
- Middle East and Africa9.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 91 | 93 | 96 | 89 | 98 | 98 | 94 |
| Lonza Group | 76 | 82 | 72 | 82 | 81 | 89 | 80 |
| Sartorius AG | 69 | 70 | 72 | 81 | 71 | 77 | 73 |
| Miltenyi Biotec | 60 | 72 | 64 | 74 | 74 | 79 | 71 |
| Cytiva (part of Danaher Corporation) | 58 | 73 | 57 | 54 | 65 | 52 | 60 |
| Viralgen | 46 | 47 | 57 | 47 | 53 | 54 | 51 |
| REGENXBIO | 57 | 41 | 59 | 49 | 55 | 42 | 51 |
| Oxford Biomedica | 50 | 57 | 57 | 40 | 54 | 36 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Lonza Group
- Sartorius AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Lonza Group | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Sartorius AG | ✓ | ◐ | ✓ | ✓ | − | ✓ |
| Miltenyi Biotec | ✓ | − | − | ✓ | ◐ | ◐ |
| Cytiva (part of Danaher Corporation) | ◐ | − | − | − | ◐ | − |
| Viralgen | − | − | ◐ | − | ◐ | ◐ |
| REGENXBIO | ◐ | − | ◐ | ◐ | − | − |
| Oxford Biomedica | − | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific94
2Lonza Group80
3Sartorius AG73
4Miltenyi Biotec71
5Cytiva (part of Danaher Corporation)60
6Viralgen51
7REGENXBIO51
8Oxford Biomedica49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificLonza Group
Challenger2
Strong scale, closing on the leaders.
Sartorius AGMiltenyi Biotec
Contender1
Focused players with pockets of strength.
Cytiva (part of Danaher Corporation)
Niche3
Specialists in a single segment or region.
ViralgenREGENXBIOOxford Biomedica
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vector Type in North America, then scale across Gene Vector Market — a $112M beachhead inside a $1.61B market.
Beachhead (SOM)$112Mobtainable near-term
Serviceable (SAM)$599Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Adenoviral Vectors
Best fit — highest urgency & budget in Vector Type.
Economic buyer79 fit
Lentiviral Vectors
Strong fit — clear ROI and a fast path to value.
End user64 fit
Adeno-Associated Viral (AAV) Vectors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vector Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel30%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Vector Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Gene Vector Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified21%
Evaluation11%
Closed-won6%
$12.6KCAC
$59KLTV
4.7:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Gene Vector Market is a resilient opportunity — $4.81B by 2033, compounding at 4.2%.
TAM · 2025$3.46Btoday
TAM · 2033$4.81Bforecast
CAGR4.2%2027–2033
Cumulative$36.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.81BTotal addressable market
SAM$1.65BServiceable available market
SOM$318MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.2% CAGR
Demand compounds through 2033, outpacing GDP across Vector Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vector Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.81BLarge & growingTAM by 2033 at 4.2% CAGR
$1.65BServiceable nowreachable with today’s model
$318MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.75BBear2.7% CAGR
$4.81BBase4.2% CAGR
$6.15BBull5.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Gene Vector Market — a $5.63B market by 2033. Plan: grow share from 8.8% to 17.4%.
Market size · 2033$5.63Btotal addressable
Market CAGR5.0%2027–2033
Target share17.4%from 8.8% today
Revenue ambition$980Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 17.4% | Ahead |
| Revenue | $541M | $980M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.8% | 40.2% | At risk |
| Customer retention | 90.7% | 96.7% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vector Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vector Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $117M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Vector Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Gene Vector Market conversation — a $5.25B market you can size, segment and defend in minutes.
Market size · 2033$5.25Btotal opportunity
Growth7.7%CAGR to 2033
Addressable buyers1,067+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vector Type
Goal Grow share in Vector Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 4 mopayback period
$54K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Thermo Fisher ScientificLonza GroupSartorius AGMiltenyi BiotecCytiva (part of Danaher Corporation)ViralgenREGENXBIOOxford Biomedica+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Gene Vector Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Gene Vector Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Gene Transfer Instrument Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportGenetic Virus Vector Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportGenetic Toxicology Testing Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportGenetic Toxicology Market
Market size, share, segmentation and regional forecast.
$920M market · 2025 base year
View reportGenetic Toxicity Impurity Testing Services Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportGenetic Testing Kits for Animals Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportGenetic Testing for Consumers (DTC) Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportGenetic Testing for Cancer Risk Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportGenetic Stability Testing Market
Market size, share, segmentation and regional forecast.
$662M market · 2025 base year
View reportGenetic Obesity Drug Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportGenetic Modification Therapies Clinical Applications Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportGenetic Material Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.